Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease. Preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University.
In a press release published Jan. 24, Silo said that its drug SPC-14—one formulation of which contains ketamine and another, undisclosed FDA-approved drug—reduced signs of anxiety, depression and repetitive behaviours in mice. SPC-14 was previously found to be effective at increasing memory function in mice as well.
“We believe today’s announcement, along with our past studies of SPC-14 conducted in female rodents, lends credibility to our discovery of a therapeutic that could bring relief to patients and families suffering from Alzheimer’s disease,” Silo CEO and founder Eric Weisblum said in the release. He added that the company is looking forward to data “needed to advance SPC-14 to a clinical study.”
https://silopharma.com/about/